Orthobiologics Strategy: FDA Issues New Warning about Sales of Unapproved Products

By Scott Bruder

Orthobiologics Strategy: FDA Issues New Warning about Sales of Unapproved Products
FDA doubled down on its enforcement commitment for Human Cell and Tissue Products after its enforcement discretion ended in May.

Member-Only Content

SUBSCRIBE Login

Product Labels: PRP/Cell-Based/Osteoinductive Materials

Tags: Regulatory